Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Calcul of the ratio PaO2/FiO2
研究概览
简要总结
The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation).12 immunocompetent patients will compare the successive use of oxygen therapy delivery systems Optiflow®/Ospal® and 12 immunodeficient patients will compare the successive use of systems Optiflow®/Non invasive ventilation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient hospitalized in the intensive care unit of Nantes University Hospital
- •Signed informed consent
- •Patient with not hypercapnic acute hypoxemic respiratory failure
- •Immunocompetent and immunodeficient patient
排除标准
- •Age < 18 years
- •Pregnancy
- •Contra-indication to non invasive ventilation
- •Allergy to xylocaine
- •Coagulation troubles
- •Tracheotomized patient
- •Urgent indication to intubation
- •Hypercapnic acute respiratory failure
- •Acute pulmonary edema
- •Face or nose malformation
研究组 & 干预措施
VNI/Optiflow, Immunodeficient patients
VNI = non invasive ventilation
干预措施: Oxygen therapy delivery systems (Other)
Optiflow/VNI, Immunodeficient patients
VNI = non invasive ventilation
干预措施: Oxygen therapy delivery systems (Other)
Ospal/Optiflow, Immunocompetent patients
干预措施: Oxygen therapy delivery systems (Other)
Optiflow/Ospal, Immunocompetent patients
干预措施: Oxygen therapy delivery systems (Other)
结局指标
主要结局
Calcul of the ratio PaO2/FiO2
时间窗: one hour after each system used
The main objective of this study is to evaluate the efficiency of the oxygen therapy delivery system Optiflow® compared to 2 others standard oxygen therapy delivery systems (Ospal®, non invasive ventilation) by calculating the ratio PaO2/FiO2
次要结局
- number of participants with adverse events
- measure of respiratory frequency and blood gas
- measure of positive and expiratory pressure